Psychedelics R&D Biotech Biomind Labs Inc. BMNDF has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 study of its proprietary 5-MeO-DMT-based drug candidate BMND08 for the treatment of depression and anxiety in people with Alzheimer’s types of cognitive impairment.

Alejandro Antalich, CEO of Biomind, sees this move as a new milestone that strengthens the company’s “vertically integrated” strategy and potentially alleviates the suffering of people living with this condition.

“Over the last few decades, science has shown that life expectancy can be extended, but this finding may not be as good as expected. For example, does it make sense to live longer if we can’t even remember our name or recognize a close relative? The consequences of the current lifestyle, routine neurological long-term effects of Covid-19 and the lack of brain training have made neurodegenerative diseases widespread,” said Antalich.

For this reason, he explains, Biomind’s main drive is to find a solution to these health problems and potentially improve patients’ neuroplasticity. “Anyone who has a loved one with a neurodegenerative disease like Alzheimer’s would do anything to stop the invisible, slow and irreversible disease that is completely wiping out quality of life,” said the CEO.

What the new, sublingual route of administration enables is, among other things, “convenient dosing for geriatric and psychiatric uncooperative patients with dysphagia (difficulty swallowing)”, rapid absorption, predictable potency, reduced interactions with other pharmaceuticals and foods, and ease of administration compared to other delivery technologies.

“The main goal in developing this formulation was based on providing a scalable formulation that is cost-effective, convenient for repeated and prolonged use, and pain-free,” explains Dr. Paola Diaz, CSO of Biomind…